Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,749 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT07822880 |
| not yet recruiting |
| Phase 4 |
| 30 |
| Eli Lilly and CompanyINDUSTRY |
| 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.(REVIVE) | recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab(CROWD) | recruiting | Phase 4 | 38 | Idris BahceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 4 | 12 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC | recruiting | Phase 4 | 78 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07567313 | Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy | not yet recruiting | Phase 4 | 166 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies(PROMETHEE) | recruiting | Phase 4 | 500 | GFPC InvestigationOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence(GASTIVA) | recruiting | Phase 4 | 5,384 | Samsung Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | active not recruiting | Phase 4 | 41 | Guangdong Association of Clinical TrialsOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens(AmiCARE) | not yet recruiting | Phase 4 | 122 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | recruiting | Phase 4 | 60 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05219162 | Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).(GPS) | completed | Phase 4 | 182 | AstraZenecaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | recruiting | Phase 4 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study | not yet recruiting | Phase 4 | 30 | Fujian Medical University Union HospitalOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC | not yet recruiting | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT05748093 | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat(OSIBOOST 2) | unknown | Phase 4 | 60 | Maastricht University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05583188 | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC(VIGOR) | terminated | Phase 4 | 5 | Galvanize Therapeutics, Inc.INDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06357598 | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer(PILOT) | unknown | Phase 4 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04401059 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study(SELECT-2) | unknown | Phase 4 | 744 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06010277 | Folinic Acid for Prevention of Pemetrexed-induced Toxicity(FLEX) | unknown | Phase 4 | 50 | Amphia HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT04381494 | Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.(ON TRAX) | terminated | Phase 4 | 40 | AstraZenecaINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05785208 | Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.(TEMPLE-2) | unknown | Phase 4 | 122 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT05782764 | A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | unknown | Phase 4 | 30 | Xuzhou Medical UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05387109 | Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer(pcwaintrl) | unknown | Phase 4 | 41 | Tang-Du HospitalOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | terminated | Phase 4 | 81 | Radboud University Medical CenterOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT03655834 | Dose Individualization of Pemetrexed - IMPROVE-III(IMPROVE-III) | completed | Phase 4 | 10 | Radboud University Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC | recruiting | Phase 4 | 70 | University of CreteOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05098990 | Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC | unknown | Phase 4 | 328 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT03200600 | Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery | terminated | Phase 4 | 126 | Peking University First HospitalOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03853551 | Osimertinib Study in Indian Patients | completed | Phase 4 | 60 | AstraZenecaINDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03607149 | Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies(PKAPIR) | completed | Phase 4 | 11 | Centre Georges Francois LeclercOTHER | 1 | May 24, 2021 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials